Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

Summary

The goal of this study is to start treatment with the NOTCH1 inhibitor brontictuzumab in an attempt to control tumors and prolong survival. The therapy involves participant being given the drug brontictuzumab to treat adenoid cystic carcinoma (ACC) with NOTCH 1 mutations. This is considered an investigational treatment.

Timeline

Start

2015-12-29

Primary completion

2016-03-06

Completion

2016-03-06

Drugs

Indications